For six patients in Berlin whose bodies had resisted every advanced treatment medicine could offer, a single infusion of genetically reprogrammed immune cells has opened a door that years of failed therapies had kept shut. Researchers at Charité - Universitätsmedizin Berlin have applied CAR T-cell therapy — long a tool of oncology — to severe rheumatoid arthritis, coaxing the immune system not merely into silence but into something resembling renewal. Three of the six participants entered sustained, medication-free remission, raising a quiet but profound question: what if the immune system, gi
Cancer Therapy Shows Promise in Severe Rheumatoid Arthritis, Achieving Remission in Early Trial
Six patients with severe treatment-resistant rheumatoid arthritis experienced marked disease reduction, with three achieving medication-free remission and improved quality of life.
Three patients no longer needed any arthritis medication
Mark
So this is cancer therapy being repurposed for autoimmune disease. How different is the actual mechanism?
Mimi
The machinery is identical—you're still modifying T cells to recognize a surface marker and destroy cells carrying it. But the target flips. In cancer, you're hunting tumor cells. Here, you're hunting the immune cells that are causing the problem.
Luke
And that's the part I want to press on. We know CAR T works in blood cancers because those cells are circulating. Rheumatoid arthritis B cells are hiding in joints, bone marrow, lymph nodes. Did the trial actually confirm the engineered cells reached those deep locations, or is that inference?
Mimi
They measured autoantibody levels dropping sharply, and they found that when B cells recovered, the disease-driving ones were gone but vaccine-induced antibodies remained. That's pretty strong evidence the cells reached the reservoirs.
Mark
Three out of six achieved remission without medication. That sounds remarkable for people who'd failed eight different drugs.
Mimi
It is. But one patient's remission didn't hold. And the other three showed improvement but didn't reach full remission. So responses varied.
Luke
How varied? The source says "some did not achieve a complete response" and one relapsed. That's vague. We don't know if the other two had partial remission or something else.
Mark
What about the immune system reset idea? Is that proven or still theoretical?
Mimi
The evidence is suggestive. When B cells came back, they were predominantly naive—hadn't been shaped by disease yet. The pathological ones were gone in almost all patients. But whether that constitutes a true reset, or how long it lasts, we don't know.
Luke
And that's the honest answer. Long-term effects are unknown. This is a six-person trial with one year of follow-up. That's encouraging, but it's not proof of anything yet.
Mark
So what's the real question the next phase needs to answer?
Mimi
Whether CAR T produces stronger or longer-lasting effects than existing B-cell-targeting drugs, and whether it truly resets immune memory rather than just suppressing it temporarily.
Luke
And whether the safety profile holds in a larger group. Cytokine release syndrome was mild here, but that's six people. You need more data.
Der Puls
- Six patients who had exhausted up to eight biologic drugs found themselves with no remaining conventional options, their joints still inflamed and their lives still diminished by a disease their own bodies were waging.
- A single infusion of CAR T cells — engineered to hunt and eliminate the disease-driving B cells hiding in joints, bone marrow, and lymph nodes — triggered a sweeping immune reset that standard drugs rarely achieve.
- Three participants reached sustained, medication-free remission through a full year of follow-up, while all six showed meaningful reductions in disease activity, a result that stunned researchers given the depth of prior treatment failure.
- Crucially, the immune system did not simply go quiet — it rebuilt itself with naive B cells largely free of pathological memory, while protective antibodies from old vaccinations remained intact.
- The trial is small, one remission did not hold, and long-term immune consequences are still unknown, keeping the therapy firmly in experimental territory as larger comparison studies now begin.
For six patients in Berlin whose bodies had resisted every advanced treatment medicine could offer, a single infusion of genetically reprogrammed immune cells has opened a door that years of failed therapies had kept shut. Researchers at Charité - Universitätsmedizin Berlin have applied CAR T-cell therapy — long a tool of oncology — to severe rheumatoid arthritis, coaxing the immune system not merely into silence but into something resembling renewal. Three of the six participants entered sustained, medication-free remission, raising a quiet but profound question: what if the immune system, given the right instruction, can learn to forget its own cruelty?
Six patients with severe rheumatoid arthritis arrived at a Berlin hospital carrying years of failure — some had tried as many as eight different biologic drugs, the most advanced therapies available, and none had worked. Their joints still swelled. Their pain persisted. Researchers at Charité - Universitätsmedizin Berlin then attempted something borrowed from cancer medicine: a single infusion of genetically modified immune cells designed to hunt down the very cells driving the disease.
The therapy, known as CAR T-cell therapy, works by extracting a patient's own T cells, reprogramming them in the laboratory to recognize a surface marker called CD19 found on disease-driving B cells, and returning them in a single dose. Before the infusion, patients receive a brief course of chemotherapy to make room for the engineered cells to work. What follows is a kind of immune reset — the CAR T cells eliminate nearly all CD19-positive B cells, including those hiding deep in bone marrow, lymph nodes, and joint tissue where conventional drugs rarely reach. When the B-cell population recovers over the following months, it does so largely without the pathological memory that had been fueling inflammation.
The results, published in Nature Medicine, were striking. All six participants — three women and three men aged 31 to 69 — showed marked reductions in disease activity. Three achieved sustained remission through a full year of follow-up without any rheumatoid arthritis medication. One patient's remission did not hold, and the others improved without reaching full remission. Autoantibodies associated with the disease dropped sharply, and when the immune system rebuilt itself, it did so predominantly with naive B cells. Notably, protective antibodies from earlier vaccinations against chickenpox and tetanus remained detectable — the immune system appeared to shed its harmful memory while retaining useful traces of the old.
The safety profile was encouraging: all six experienced only mild-to-moderate cytokine release syndrome, a manageable inflammatory response, with no severe complications. Still, the researchers are measured in their claims. The sample is small, long-term immune effects remain unknown, and the therapy is still experimental. A follow-up trial called COMPARE will enroll ten more patients and pit CAR T-cell therapy directly against an approved B-cell-targeting drug, testing whether the engineered cells produce deeper or more lasting effects. If larger studies hold, this approach could one day offer not a lifelong regimen of immune suppression, but a single intervention that resets the immune system itself.
Six people with severe rheumatoid arthritis walked into a Berlin hospital carrying a decade of failed treatments. They had tried as many as eight different biologic drugs—the most advanced therapies available—and none had worked. Their joints still swelled. Their pain persisted. Their lives remained constrained by a disease their own immune system was waging against them. Now researchers at Charité - Universitätsmedizin Berlin have reported something unexpected: a single infusion of genetically modified immune cells put three of those six patients into sustained remission without any arthritis medication at all.
The treatment is called CAR T-cell therapy, and it was borrowed from cancer medicine. The logic is straightforward but radical. In cancer patients, doctors extract T cells—immune cells that normally hunt down infected or abnormal tissue—and reprogram them in the laboratory. They equip each cell with an artificial receptor, a kind of molecular search engine designed to find and destroy tumor cells. For rheumatoid arthritis, the target is different. Instead of cancer cells, the engineered T cells hunt disease-driving B cells, the immune memory cells that hide deep in joints, bone marrow, and lymph nodes, churning out antibodies that attack the body's own tissue.
The identifying marker on these harmful B cells is a surface molecule called CD19. Think of it as a name tag. The modified T cells are programmed to recognize CD19, seek it out wherever it hides in the body, and eliminate it. Before receiving the infusion, patients undergo a brief course of chemotherapy to create space for the engineered cells to multiply and work. Then the cells are returned in a single dose. What happens next is a kind of immune system reset. The CAR T cells wipe out nearly all CD19-positive B cells—both the disease-driving ones and the normal ones. When the B-cell population recovers over the following months, it does so without the pathological memory that had been driving the inflammation.
The trial enrolled six patients, three women and three men ranging in age from 31 to 69. All had exhausted conventional options. The results, published in Nature Medicine, showed disease activity dropped markedly in every participant. Three achieved what researchers call sustained remission—a state of disease inactivity lasting through the one-year follow-up period without any rheumatoid arthritis medication. One patient's disease returned after an initial medication-free period, and the others showed improvement but did not reach full remission. Still, for a group that had found no relief from eight different advanced therapies, the outcome was striking.
What made the result particularly significant was what researchers found when they looked deeper. The engineered cells did not simply suppress inflammation in the joints. They actually reached the disease-driving B cells hiding in protected locations—deep inside bone marrow, in lymph nodes, in joint tissue itself—places that conventional drugs struggle to penetrate. Over the following year, the autoantibodies associated with rheumatoid arthritis dropped sharply. When the B-cell system recovered, it did so with predominantly naive B cells that had not yet been shaped by disease. The pathological B cells that had been present before treatment were largely gone. Remarkably, protective antibodies from earlier vaccinations—against chickenpox, tetanus—remained detectable, suggesting the immune system retained some useful memory even as it shed the harmful kind.
The safety profile was encouraging. All six patients experienced only mild-to-moderate cytokine release syndrome, a temporary inflammatory response that was readily managed. There were no severe neurological complications, no serious adverse events, and infections were rare. But the researchers are careful about what they claim. This is the first trial of its kind in rheumatoid arthritis. The sample is small. Long-term effects on the immune system remain unknown. One patient's remission did not hold. The therapy is still experimental.
The next phase of the trial, called COMPARE, will enroll ten additional patients and compare CAR T-cell therapy directly with an already-approved rheumatoid arthritis drug that also targets B cells. That comparison should reveal whether the engineered cells produce stronger or longer-lasting effects and whether they truly reset immune memory in a way existing treatments cannot. If larger studies confirm these early results, CAR T-cell therapy could eventually offer a new path for people with severe, treatment-resistant rheumatoid arthritis—not a lifelong regimen of immune-suppressing drugs, but a single intervention that might reset the immune system itself.
Bemerkenswerte Zitate
Disease activity decreased markedly in all six patients. During follow-up of up to one year, three patients were in sustained remission without any medication for rheumatoid arthritis. This is particularly remarkable given that none of the established treatments had previously been able to relieve their symptoms adequately.— Gerhard Krönke, lead researcher, Charité
When the B-cell system later recovered, predominantly naïve B cells that had not yet been shaped by the disease returned. In contrast, the B cells directed against the body's own tissues that had been present before treatment were no longer detectable in almost all patients, an indication that the treatment may indeed be able to reset the pathological immune memory.— David Simon, trial designer, Charité
Möchten Sie die ganze Geschichte?
Das Original lesen bei Science Daily ↗
Health & Medicine